Briggs Morrison
Directeur/Membre du Conseil chez CARISMA THERAPEUTICS, INC.
Fortune : 1 M $ au 30/04/2024
Profil
Briggs W.
Morrison is currently the Chief Executive Officer & Director at Crossbow Therapeutics, Inc., the Independent Chairman at Auron Therapeutics, Inc., the Director at Arvinas Operations, Inc., the Lead Independent Director at Arvinas, Inc., the Director at ImmunoMet Therapeutics, Inc., the Director at Alliance for Clinical Research Excellence & Safety, the Director at CTx Operations, Inc., the Independent Director at Repare Therapeutics, Inc., the Director at Werewolf Therapeutics, Inc., the Director at Photys Therapeutics, Inc., the Independent Director at Carisma Therapeutics, Inc., the EXECUTIVE PARTNER at MPM BioImpact, Inc, and a member of the Investment Committee at MPM BioImpact LLC.
Formerly, Dr. Morrison served as the Chairman at Transcelerate Biopharma, Inc., a Director at BioSight Ltd., an Independent Director at Codiak BioSciences, Inc., an Independent Director at NextCure, Inc., an Independent Director at Oncorus, Inc., a Director at RIFT biotherapeutics, Inc., a Director at Redona Therapeutics, Inc., a Director at Syndax Pharmaceuticals, Inc., and the Head-Medical Affairs, Safety & Regulatory Affairs at Pfizer Inc. He also held the position of Chief Medical Officer at AstraZeneca PLC and Vice President-Clinical Sciences at Merck Research Laboratories Massachusetts LLC.
Dr. Morrison obtained his undergraduate degree from Georgetown University and his doctorate from The University of Connecticut School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARVINAS, INC.
0,03% | 31/03/2024 | 19 976 ( 0,03% ) | 631 242 $ | 30/04/2024 |
| 08/03/2024 | 17 836 ( 0,02% ) | 366 887 $ | 30/04/2024 | |
| 21/06/2023 | 15 523 ( 0,04% ) | 96 398 $ | 30/04/2024 | |
| 06/06/2023 | 12 175 ( 0,03% ) | 19 967 $ | 30/04/2024 | |
REPARE THERAPEUTICS INC.
0,01% | 15/04/2024 | 4 800 ( 0,01% ) | 15 120 $ | 30/04/2024 |
Postes actifs de Briggs Morrison
| Sociétés | Poste | Début |
|---|---|---|
| ARVINAS, INC. | Directeur/Membre du Conseil | 01/06/2018 |
| REPARE THERAPEUTICS INC. | Directeur/Membre du Conseil | 01/06/2017 |
| WEREWOLF THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/11/2019 |
| CARISMA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/07/2020 |
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | - |
Auron Therapeutics, Inc.
 Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Président | - |
Photys Therapeutics, Inc.
 Photys Therapeutics, Inc. Medical SpecialtiesHealth Technology Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation. | Directeur/Membre du Conseil | - |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Directeur/Membre du Conseil | 01/07/2020 |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Directeur/Membre du Conseil | - |
| ░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Briggs Morrison
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Briggs Morrison
| Georgetown University | Undergraduate Degree |
| The University of Connecticut School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 9 |
|---|---|
| PFIZER, INC. | Health Technology |
| ARVINAS, INC. | Health Technology |
| ASTRAZENECA PLC | Health Technology |
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| ONCORUS, INC. | Health Technology |
| REPARE THERAPEUTICS INC. | Health Technology |
| NEXTCURE, INC. | Health Technology |
| WEREWOLF THERAPEUTICS, INC. | Health Technology |
| CARISMA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 15 |
|---|---|
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Health Technology |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Alliance for Clinical Research Excellence & Safety
 Alliance for Clinical Research Excellence & Safety Miscellaneous Commercial ServicesCommercial Services Alliance for Clinical Research Excellence & Safety is a non-governmental organization that builds, implements, and maintains comprehensive systems. The non-profit company is based in Cambridge, MA. The company was founded by Greg Koski. | Commercial Services |
RIFT biotherapeutics, Inc.
 RIFT biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services RIFT biotherapeutics, Inc. operates as a therapeutic antibody company that focuses on immuno-oncology targets outside of the T-cell space. It generates therapeutic antibodies that harness the immune system, to target cancers in areas of unmet needs. The company was founded by Miguel A. de los Ríos, Cornelia Bentley, and Jeff Pitman in 2015 and is headquartered in San Diego, CA. | Commercial Services |
ImmunoMet Therapeutics, Inc.
 ImmunoMet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImmunoMet Therapeutics, Inc. operates as a development-stage biopharmaceutical company that develops and commercializes novel oncology products. It offers novel technology that designed to disrupt cancer cell growth and enhance anti-cancer immunity. The company was founded in July 2015 and is headquartered in Houston, TX. | Health Technology |
BioSight Ltd.
 BioSight Ltd. Miscellaneous Commercial ServicesCommercial Services BioSight Ltd. is a clinical stage biotechnology company engaging in the development of therapeutics for hematological malignancies and disorders. The company was founded by Stela Gengrinovitchan and Mark Gengrinovitch on November 10, 1999 and is headquartered in Lod, Isreal. | Commercial Services |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Health Technology |
Redona Therapeutics, Inc.
 Redona Therapeutics, Inc. BiotechnologyHealth Technology Redona Therapeutics, Inc.operates as a biotechnology company focused on the modulation of non- RNA (ncRNA) function to treat cancer and other human diseases. It uses small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company was founded by George Daley, Richard Gregory, Frank Slack, and Piotr Sliz and is headquartered in Watertown, MA. | Health Technology |
Codiak BioSciences, Inc.
 Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. Codiak BioSciences was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
Photys Therapeutics, Inc.
Photys Therapeutics, Inc. Medical SpecialtiesHealth Technology Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation. | Health Technology |
Auron Therapeutics, Inc.
Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Commercial Services |
Bioimpact Capital LLC
Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Crossbow Therapeutics, Inc.
 Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer. | Health Technology |
